KDR and renal cell carcinoma: For further analyses, we performed combined treatment with disulfiram and sunitinib in vitro and in vivo in RCC cells because sunitinib, which mainly inhibits angiogenesis through suppression of vascular endothelial growth factor receptor (VEGFR), is clinically used as a first-line and second-line therapy for patients with advanced RCC.